US FDA approves updated COVID shots ahead of fall and winter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to US FDA approves updated COVID shots ahead of fall and winter
August 23, 2024 7:50 AM EDT
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Conclusions Todays announcement that FDA has approved Modernas new formulation for its COVID-19 vaccine (2024-2025 formulation) targeting the KP.2 variant of SARS-CoV-2, the variant based on guidance from the FDA. This approval follows a... More
August 23, 2024 7:03 AM EDT
Moderna, Inc. (NASDAQ: MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The marketing authorization follows the Positive Opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway.
"The... More
